Alluvi, formerly BI 4744, represents a promising advance in weight control therapy. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://socials360.com/story12845506/alluvi-a-detailed-examination-into-the-medication-s-potential